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Summary
Recently, haploinsufficiency mutations in the melano-
cortin-4 receptor gene (MC4-R) were detected which
were assumed to lead to the phenotype of extreme obe-
sity. Previously, we detected three obese carriers among
306 index patients. Here we describe the detection of
one haploinsufficiency carrier in an additional study
group of 186 obese individuals. We subsequently gen-
otyped and phenotyped 43 family members of these four
index patients, two of whom were second-degree cous-
ins. A total of 19 carriers were identified. Extreme obe-
sity was the predominating phenotype. However, mod-
erate obesity occurred in three of the carriers. No other
specific phenotypic abnormalities were detected. Female
haploinsufficiency carriers were heavier than male car-
riers in the respective families, a finding similar to find-
ings in MC4-R–knockout mice. In conclusion, our data
fully support the etiologic role of MC4-R haploinsuffi-
ciency mutations in obesity.
Introduction
MC4-R (MIM 155541) is a G-protein–coupled seven-
transmembrane receptor primarily expressed in the hy-
pothalamus, hippocampus, and thalamus (Gantz et al.
1993). The receptor is implicated in the central regu-
lation of body weight: MC4-R is activated by a-me-
lanocyte-stimulating hormone (MSH), which is derived
from pro-opiomelanocortin and is antagonized by
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agouti-related protein. a-MSH induces weight loss,
whereas the ectopic expression of agouti protein results
in obesity in the agouti mice (Fan et al. 1993; Lu et al.
1994). Additional evidence for the role of MC4-R in
weight regulation stems from both a knockout model in
mice (Huszar et al. 1997) and haploinsufficiency mu-
tations in humans (Vaisse et al. 1998; Yeo et al. 1998;
Hinney et al. 1999). In MC4-R–knockout mice, an in-
creased body weight was discernible by age 5 wk. By
age 15 wk, homozygous mutant females were, on av-
erage, twice as heavy as their wild-type littermates,
whereas homozygous mutant males were ∼50% heavier
than wild-type controls. Mice heterozygous for the
MC4-R knockout showed a weight gain intermediate to
that seen in wild-type and homozygous mutant litter-
mates, thus demonstrating a gene dosage effect of MC4-
R ablation on body-weight regulation. The food intake
of homozygous mutants was increased by ∼50% in com-
parison to that in wild-type sibs (Huszar et al. 1997).
Recently, mutations leading to haploinsufficiency for
MC4-R were detected in obese individuals by means of
systematic mutation screens of the MC4-R. Three dif-
ferent haploinsufficiency mutations have currently been
described: Vaisse et al. (1998) screened 43 obese pro-
bands and detected a heterozygous 4-bp insertion at co-
don 244 in one of them. Five family members of this
index patient who also harbored the mutation were all
extremely obese; the LOD score was 1.5. Yeo et al.
(1998) screened 63 obese probands and detected a young
index patient heterozygous for a 4-bp deletion at codon
211. The father, who had a body-mass index (BMI) of
41 kg/m2, was a mutation carrier, too. Hinney et al.
(1999) also observed this deletion in both an extremely
obese female adolescent and her similarly obese mother.
In addition, the screening of 306 extremely obese chil-
dren and adolescents led to the identification of two
independently ascertained index patients with a non-
sense mutation at codon 35. This presumably results in
a receptor protein being truncated at the extracellular
domain. Both patients also harbored a missense muta-
tion at codon 37 (Hinney et al. 1999). Whereas these
three studies strongly suggest that haploinsufficiency
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mutations underly the obesity observed in the carriers,
the causal relationship has not been proven. Thus, in
contrast to the large number of obese individuals
screened, only a limited number of lean controls have
been screened (Hinney et al. 1999). Furthermore, be-
cause it can be expected, a priori, that either one or both
parents of an extremely obese index patient are also
obese, the observation of cosegregation of these muta-
tions with the obesity phenotype in the limited number
of informative meioses cannot be viewed as unequivocal
evidence for a causal relationship.
Several other allelic variants of MC4-R have been
identified (Gu et al. 1999; Hinney et al. 1999). In in
vitro assays, one of these mutations (Ile137Thr) was
found to severely impair ligand binding and signaling,
raising the possibility that this mutation may contribute
to the obese phenotype. However, the effect of the
Ile137Thr allele seems to be recessive (Gu et al. 1999).
For the purpose of this study, we have recontacted the
parents of the index patients with haploinsufficiency mu-
tations, to genotype and phenotype additional family
members. Furthermore, we extended the mutation
screen to another 186 extremely obese children and ad-
olescents to detect further mutations leading to hap-
loinsufficiency and, if this was successful, to extend the
study to the respective families. Our intention was to
assess whether haploinsufficiency mutations indeed co-
segregate with the phenotype obesity and, if they do, to
delineate the phenotype associated with these mutations.
Material and Methods
In our initial study, 306 extremely obese German chil-
dren and adolescents (mean BMI 34.4  6.6 kg/m2,
mean age 14.3 2.4 years) were screened, by SSCP, for
mutations in MC4-R, leading to the identification of 3
adolescents with haploinsufficiency (Hinney et al. 1999).
For this study, we screened an additional 186 obese in-
dex patients (mean BMI 30.92 5.79 kg/m2, mean age
13.19  2.67 years) by SSCP. Bidirectional sequencing
of PCR products showing an SSCP pattern similar to
the pattern observed in the nonsense mutation carriers
was performed as described elsewhere (Hinney et al.
1999).
The parents of all identified haploinsufficiency carriers
were recontacted and were asked to participate in an
extended family study. At the time of the original in-
vestigation of index patients, parents had given written
informed consent to be recontacted in case a medically
relevant molecular finding emerges. All contacted nu-
clear families, in turn, asked other family members to
participate in the study. Participating family members
gave their written informed consent in accordance with
the Ethics Committee of the University of Marburg.
The family members (fig. 1; pedigrees A–C with n =
, , and family members, respectively) were21 n = 18 n = 8
contacted and were examined at their homes. The fol-
lowing variables were measured: body weight and
height; body composition, as determined with bioelectr-
ical impedance analysis (BIA) (Data Input 2000-S); and
waist and hip circumference. Age- and sex-specific BMI
percentiles were calculated on the basis of the large and
representative German National Nutrition Survey (He-
bebrand et al. 1996). To illustrate the BMI distribution
of both carriers and noncarriers of haploinsufficiency
mutations in relation to the BMI distribution observed
in the general population, we plotted BMIs of the as-
certained family members into BMI percentile curves on
the basis of anthropometric data obtained from the
German National Nutrition Survey. The percentiles were
calculated as described by Cole et al. (1998), for indi-
viduals aged 8–70 years. Blood sampling was performed
to allow for DNA isolation and for determination of
serum leptin levels with a radioimmunoassay (Blum
1997).
On the basis of the findings from a semistructured
interview that included the eating disorders module of
the M-Composite International Diagnostic Interview
(Wittchen et al. 1995), the following data were obtained
from all participating family members: eating disorders,
diet habits, weight history as of early childhood, and
history of medical disorders, including assessment of
possible effects on body weight. All family members
were asked if they had been in psychological treatment
related or unrelated to their obesity. Furthermore, each
individual was questioned as to their subjective opinion
on the cause of their obesity.
Ascertained family members were genotyped by
means of SSCP. Additionally, for the nonsense mutation,
PCR was performed with allele-specific primers (forward
primers MC4R-Y 5′-GTCCCTTGGAAAAGGCTAC-3′
for the wild-type al le le and MC4R-STOP 5 ′-
GTCCCTTGGAAAAGGCTAA-3′ for the 35-Stop allele,
respectively, both with MC4R-1R 5′-GACAGCACTAC-
TATCTGAGT-3′ as a reverse primer).
An exact 95% confidence interval for the frequency
of haploinsufficiency mutations in German children and
adolescents with extreme obesity was calculated as de-
scribed in StatXact (1996). LOD scores were calculated
by use of FASTLINK (Cottingham et al. 1993).
We investigated whether the median age- and sex-
adjusted maximum lifetime BMI percentile in family A
was larger in mutation carriers than in noncarriers. To
take into account residual correlation among relatives,
we performed a Monte Carlo permutation. For each
sibship, 1,000,000 permutations were conducted sepa-
rately. The system time was used as seed for the exper-
iment via the GAUSS (1994) procedure RNDU, which
uses a multiplicative-congruential method. The test sta-
tistic was the sum of the standardized sibship-rank sums.
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Figure 1 Three pedigrees ascertained via four index patients with haploinsufficiency mutations in MC4-R. A 4-bp deletion at codon 211
in pedigree A and a nonsense mutation at codon 35 in pedigrees B and C underly the haploinsufficiency (for more details see table 1).
Means and variances were calculated under the null hy-
pothesis. The midrank method was used to handle ties.
Mean BMIs of carriers of the nonsense mutation were
compared with mean BMIs of the carriers of the 4-bp
deletion by means of the t-test. This test, however, does
not adjust for residual correlation between relatives, as
discussed in detail by (for example) Gu et al. (1999). If
these dependencies exist, they are most likely positive.
This would lead to an underestimation of the variance.
Hence, the results of this analysis should be interpreted
carefully.
Results
The screening of 186 children and adolescents with
extreme obesity led to the detection of a single index
patient with a haploinsufficiency mutation, which was
caused by the nonsense mutation at codon 35 of MC4-
R. This individual also harbored the missense mutation
at codon 37. Not totally unexpectedly, this patient, who
was ascertained independently of other index patients,
turned out to be related to one of the previously iden-
tified carriers of the two nonsense mutations (Hinney et
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al. 1999); the two index patients were second-degree
cousins (fig. 1, pedigree B: IV:1, IV:3). We did not iden-
tify an individual homozygous for any of the haploin-
sufficiency mutations. The exact 95% confidence inter-
val for the frequency of haploinsufficiency mutations is
between 0.2% and 2.1% for German children and ad-
olescents with extreme obesity, since we identified a total
of four carriers in 492 individuals.
Cosegregation of either the deletion (fig. 1, pedigree
A) or the nonsense mutation (fig. 1, pedigrees B and C)
with obesity was observed in 18 of the 19 identified
individuals within the three families. Only one carrier,
a male aged 60 years, (pedigree B: II:3) had a current
BMI (27.9 kg/m2) below the 90th percentile. However,
this male had had a heart attack at age 56 years and
had subsequently dieted continuously to control his
weight; his maximal BMI (on the basis of recalled weight
and measured height) had been 32.2 kg/m2 at age 54
years (96th percentile).
Six individuals (fig. 1, pedigree A: II:1, III:4; pedigree
B: II:4, III:5; and pedigree C: I:1, III:2), who were non-
carriers of one of the two haploinsufficiency mutations
or other mutations in MC4-R, also had a BMI above
the 90th percentile. Of these, four were spouses of mu-
tation carriers. Two obese noncarriers were sibs of index
patients (pedigree A III:4 and pedigree C III:2). Relevant
phenotypic data are shown in table 1.
Current and maximal lifetime BMIs and the corre-
sponding percentiles revealed that not all mutation car-
riers are or had been extremely obese (figs. 2A and 2B).
Of the 19 carriers, 16 had a current BMI percentile95,
which is used as a cutoff for super-obesity (Cronk and
Roche 1982). Nine had a BMI exceeding that of the
maximum BMI observed in the population-based con-
trol group, which encompasses ∼150–200 individuals
for each sex- and age-matched group (Hebebrand et al.
1996). The female carriers ( ) had a higher meann = 11
BMI than did the male carriers (40.9 vs. 30.0 kg/m2;
, ignoring the correlation within pedigrees).P ! .005
BMIs of four of the five female noncarriers also exceeded
the 85th percentile. Half of the 10 male noncarriers had
a BMI below the 50th percentile; three had a BMI above
the 85th percentile.
On the basis of the observation that not all carriers
were extremely obese, we calculated a LOD score post
hoc, assuming autosomal dominant inheritance and a
recombination fraction of zero and using a lifetime BMI
85th percentile to define affected individuals. This per-
centile represents the cutoff for obesity (Cronk and
Roche 1982). We used lifetime prevalences of obesity of
15% and 25%. Furthermore, we assumed a disease-al-
lele frequency of 1% and complete penetrance. We cal-
culated the phenocopy rate from these data. On the basis
of these assumptions, LOD scores equivalent to 3.79 and
3.35, respectively, were obtained. The median age- and
sex-adjusted maximal lifetime BMI percentile in family
A was larger in mutation carriers than in noncarriers
( , ignoring the correlation within pedigree A).P = .0054
The waist-hip ratio (WHR) was !1 in all male mu-
tation carriers. Three females had a WHR slightly 10.85,
which is considered the threshold value for identification
of abdominal fat accumulation in females (WHO 1998).
Serum leptin levels were within the expected range; nine
carriers had a leptin level below the median for their
age, BMI, and sex-matched reference range (Blum 1997).
Menarche occurred between ages 10 and 14 years in the
11 female carriers. Eight female and two male carriers
had a positive diet history. Three of the four index pa-
tients had been ascertained as inpatients in hospitals spe-
cializing in the treatment of extreme early-onset obesity.
Individual III:1 of pedigree A had had three inpatient
treatments, the longest of which lasted for a total of 9
mo, after which her BMI had transiently decreased to
37.28 kg/m2.
Only a single mutation carrier reported the lifetime
occurrence of eating binges fulfilling the DSM-IV re-
search criteria for a binge eating disorder, which lasted
for 3 years, ending at age 16 years. Whereas none of
the noncarriers had sought psychological treatment, five
of the mutation carriers (including four females) re-
ported psychological treatment episodes, all of which
were related to their obesity. Age at onset of obesity
among the mutation carriers was recalled as lying be-
tween infancy and 18 years.
Of the 13 carriers who were questioned about their
subjective opinions on the causes of their obesity, 11
replied that they enjoyed eating and that they considered
this aspect as a contributing factor. Otherwise, no clear
pattern emerged. Thus, some carriers stated that stress
at work ( ) or at home ( ) or frustrating expe-n = 4 n = 5
riences ( ) repeatedly led to overeating and thus con-n = 4
tributed to their obesity. Only three carriers stated that
they currently controlled their weight; several of the car-
riers had done this in the past but eventually had given
up.
Discussion
Our family study clearly substantiates that haploin-
sufficiency of the MC4-R leads to obesity that tends to
be of an early-onset type. Our data indicate a sex effect
similar to findings in MC4-R–knockout mice. In partic-
ular, the degree of adiposity in males was not as severe
as that in the females. All female carriers had a current
BMI 97th percentile. However, in contrast to findings
in the knockout mice, we did not find evidence for an
effect of the haploinsufficiency on body height. Thus,
within a sibship, the adult mutation carriers were not
of a greater height than noncarriers of the same sex and
age (table 1).
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I:2 / F 81 76 155 31.6 100 NI NC NM NM 20.7 NI
II:1 / M 49 93 175 30.4 93 NI NC .91 28.5 4.1 NI
II:2 / F 45 103 163 38.8 99 40.7 100 .90 45.5 58.1 
II:3 / M 59 76 176 24.5 26 25 26 .88 28.1 20.7 
II:4 / M 46 70 175 22.9 17 23 17 .81 27.4 2.8 
II:5 / M 50 97 171 33 97 33 97 .99 33.9 29.9 
II:6 / F 39 75 164 28.1 86 29 94 .77 39.6 16.8 
II:7 / M 42 72 180 22.2 16 22.5 59 .81 21.4 NM 
II:8 / M 39 79 177 25.2 53 NR NC .90 26.3 5.3 
II:9 / M 40 94 178 29.7 92 29.7 92 .97 NM 8.7 
II:11 / F 61 63 167 22.6 18 NR NC .93 35.5 14.9 
III:1 / F 22 117 171 40 100 42.8 100 .89 46.6 63.1 
III:2 / M 17 72 185 21 37 NR NC .80 17.6 1.1 
III:3 / F 14 79 165 29 99 29 99 .86 37.4 40.9 
III:4 / M 12 81 162 30.9 100 31 100 1.02 35.8 94.1 
III:5 / F 21 78 168 27.7 98 28 98 .75 39.7 65.8 
III:7 / M 20 110 194 29.2 98 NI NC NM NM 24.9 NI
III:8 / M 18 66 178 21 37 21 37 .79 NM 1.6 
B
II:1 / M 68 88 173 29.4 86 38.4 100 1.07 30.9 1.9 
II:2 / F 64 106 153 45.3 100 45 100 .77 58.3 91.9 
II:3 / M 60 82 171 27.9 67 32.2 96 .79 31.3 39.9 
II:4 / F 58 87 168 30.6 93 31 93 NM 43.1 NM 
III:2 / F 39 115 167 41.2 100 41.2 100 .88 52.6 47.3 
III:3 / M 41 98 176 31.6 93 NI NC .94 40.3 86.2 NI
III:5 / F 32 90 168 31.9 96 NI NC NM 33.5 41.6 NI
III:6 / M 40 110 181 33.6 99 34 99 .88 33.4 15 
IV:1 / F 19 139 165 51.1 100 40.4 100 .82 55.3 NM 
IV:3 / M 8 53 143 25.9 97 26 97 .96 40.1 88.9 
C
I:1 / M 59 97 173 32.4 96 45.1 100 .88 33.3 2.2 
I:2 / F 63 154 165 56.6 100 56.6 100 .82 54.1 128 
II:2 / F 35 144 171 49.2 100 49 100 .81 51.6 123 
III:1 / F 14 114 168 40.4 100 40 100 .85 46.5 56.5 
III:2 / F 12 59 154 24.9 97 25 97 .84 34.5 16.8 
III:3 / M 10 58 140 29.8 100 30 100 NM NM 45.9 
NOTE.—Carriers were identified by means of four index patients, who belonged to three different families (A–C) (see fig. 1).
a Genotype / indicates a haploinsufficiency carrier; / indicates a wild type carrier.
b F = female, M = male.
c NI = Not interviewed.
d NR = Not recalled.
e NC = Not calculated.
f NM = Not measured.
g Plus sign () = positive finding; minus sign () = negative finding.
The pedigrees clearly illustrate problems inherent in
the genetic analysis of the quantitative phenotype body
weight. Not unexpectedly, some obese mutation carriers
had obese spouses, presumably explaining why noncar-
rier sibs can also be obese (fig. 1, pedigree A: III:4). The
BMIs of female noncarriers were high, in comparison to
the BMI distribution in the general population; four
topped the 85th percentile (fig. 2A). Quite obviously,
other genetic and/or environmental factors, possibly in-
cluding mutations in the regulatory region of MC4-R,
are operative in these families. Accordingly, we cannot
assess the quantitative impact of the haploinsufficiency
mutations on body weight.
These considerations are further substantiated by the
fact that, in family A, which includes all of the identified
noncarriers with a BMI below the 50th percentile, the
BMIs of the carriers are also lower than those in the
other two families (figs. 2A and 2B). Our LOD-score
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Figure 2 Percentile plots (A, females; B, males) for BMI devel-
oped on the basis of a representative sample of the German population
(Hebebrand et al. 1996) and smoothed with the approach of Cole et
al. (1998) for ages 8–70 years; current BMIs of family members were
plotted into the percentile curves. Blackened symbols represent mu-
tation carriers; unblackened symbols indicate wild-type carriers. Mem-
bers of families A, B, and C are represented by triangles, squares, and
circles, respectively. A single obese female, aged 81 years, with a cur-
rent BMI of 31.6 kg/m2, was omitted from the plot, because percentile
curves are only available for ages 70 years.
calculation was only possible on a post hoc basis, after
discovery of mutation carriers with moderate obesity.
Therefore, it should be considered merely exploratory.
Despite these methodological problems, the data are
completely compatible with a cosegregation of the hap-
loinsufficiency mutations with both moderate and severe
obesity.
We cannot exclude the possibility that the two un-
derlying mutations have different phenotypic implica-
tions. Thus, the six female carriers of the nonsense
mutation in which the receptor is truncated in the
extracellular domain were currently heavier (families B
and C; mean BMI: 33.4 vs. 47.3 kg/m2; nominal P !
, ignoring the aforementioned correlation between.005
relatives) than the five females with the deletion that
presumably results in a receptor truncated in the fifth
transmembrane domain (fig. 2A and 2B). No difference
was found for the male carriers ( , ignoring theP = .68
correlation between relatives).
The phenotypic assessment of individuals with hap-
loinsufficiency mutations revealed the following inter-
esting aspects: (1) no overt evidence of diabetes mellitus
or hypertension was detected, despite extensive ques-
tioning about these frequent comorbid disorders. All car-
riers appeared quite healthy, with the exception of one
man, who had had a heart attack at age 56 years. (2)
Most mutation carriers had a gynoid pattern of fat dis-
tribution, possibly explaining the absence of comorbid
disorders. (3) Despite the extreme degree of obesity ob-
served in female carriers, only one female fulfilled life-
time criteria for a diagnosis of binge eating disorder. (4)
Not unexpectedly, four females had sought psycholog-
ical treatment for their extreme obesity. (5) Whereas ten
carriers reported past efforts to reduce their weight, re-
newed weight gain had ensued. Most carriers had given
up efforts to control their weight. (6) Serum leptin levels
were within the expected range.
In conclusion, our family data are fully compatible
with autosomal dominant inheritance of obesity result-
ing from haploinsufficiency mutations in the MC4-R.
However, in contrast to the initial observations (Vaisse
et al. 1998; Yeo et al. 1998; Hinney et al. 1999), mod-
erate obesity can also be associated with these mutations.
It appears that this applies mainly to males. Because
several noncarriers in the three ascertained families also
had BMIs in the upper range of the general population,
the extent of the quantitative effect of the mutation on
body weight is uncertain. On the basis of our phenotypic
evaluation of 19 carriers, it is possible that this subtype
of obesity is only infrequently associated with comorbid
disorders. The exact 95% confidence interval suggests
that haploinsufficiency mutations are infrequent—but
not exceedingly rare—among German children and ad-
olescents with extreme obesity. Frequency rates of such
mutations among individuals with moderate obesity re-
main undetermined. Obesity caused by MC4-R hap-
loinsufficiency mutations should be considered a diag-
nosable subgroup. Possibly, if more mutations inMC4-R
(Gu et al. 1999; Hinney et al. 1999) turn out to be
functionally relevant, the clinical importance of this di-
agnostic subgroup will increase, especially if our pre-
vious speculation holds true that carriers of functionally
relevant mutations might profit from MC4-R agonists
(Hinney et al. 1999).
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